Gilead stock pared its gains Friday after Gilead ... In the oncology business, cell therapy Tecartus and antibody drug conjugate Trodelvy lagged sales views. Tecartus treats forms of lymphoma ...

Yescarta sales grew by 9% to $414 million, and Tecartus sales surged 21% to $107 million. Research and Development: Gilead reported positive interim data from its Phase 3 PURPOSE 1 trial on ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $70.0 and $125.0 for Gilead Sciences, spanning the last three ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90 ...

Gilead Sciences, Inc., a biopharmaceutical company ... It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment ...

Gilead now expects product sales in 2022 will be between $23.8 billion and $24.3 billion, with Veklury bringing in around $2 billion. "Today our cancer therapies, Trodelvy, Yescarta and Tecartus ...

Gilead’s blood cancer treatments Yescarta and Tecartus sales rose 5% and 9%, respectively. 3) Gilead’s HIV Vaccine Is 100% Effective and Will Launch in the Summer of 2025. Gilead achieved a ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...

Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

FOSTER CITY, Calif., March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...